comparemela.com

Latest Breaking News On - Arcutis biotherapeutics company profile - Page 3 : comparemela.com

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 2 8%

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) shot up 2.8% on Tuesday . The company traded as high as $6.26 and last traded at $6.23. 631,670 shares traded hands during trading, a decline of 89% from the average session volume of 5,630,610 shares. The stock had previously closed at $6.06. Analysts Set New Price […]

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 2 8% Higher

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) were up 2.8% during trading on Tuesday . The stock traded as high as $6.26 and last traded at $6.23. 631,670 shares traded hands during trading, a decline of 89% from the average session volume of 5,630,610 shares. The stock had previously closed at $6.06. […]

Arcutis Biotherapeutics, Inc (NASDAQ:ARQT) Receives Consensus Rating of Moderate Buy from Brokerages

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among […]

Analysts Set Arcutis Biotherapeutics, Inc (NASDAQ:ARQT) PT at $24 22

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have earned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year […]

Morgan Stanley Trims Arcutis Biotherapeutics (NASDAQ:ARQT) Target Price to $10 00

Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its price target trimmed by Morgan Stanley from $45.00 to $10.00 in a research report sent to investors on Monday, Benzinga reports. The firm currently has an overweight rating on the stock. A number of other research firms have also issued reports on ARQT. Cantor Fitzgerald restated an […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.